Bioprocessing Application Notes & Case Studies

31. In-Line Monitoring Of Culture Medium Using Live Cell Metabolic Analyzer 4/7/2026

    Continuous in-line monitoring of glucose and lactate levels provides highly accurate, real-time data on cellular metabolism without the risks or data gaps associated with manual periodic sampling.

32. Novel Cardiotoxicity Evaluation Method Using iPS-Derived Cardiomyocytes 4/7/2026

    Discover how real-time monitoring of glucose and lactate in iPS-derived cardiomyocytes reveals subtle drug-induced metabolic shifts that traditional screening methods often fail to detect.

33. Microbial Integrity Of Sampling Systems After Multiple Actuations 4/6/2026

    Repeated sampling doesn’t have to mean increased contamination risk. See how microbial ingress testing demonstrates sterility integrity after up to 50 sampling actuations.

34. Tracing PS80: How LC‑MS Resolved A Potency Discrepancy 4/6/2026

    A targeted LC–MS investigation identifies molecular changes behind potency discrepancies, enabling accurate root‑cause analysis and stronger control of monoclonal antibody product quality.

35. Hunting An Unexpected mAb Variant With LC‑MS 4/6/2026

    A tailored LC–MS approach enables sensitive detection and tracking of monoclonal antibody variants, supporting deeper product characterization and better control of quality‑impacting changes.

36. Evaluation Of TFF Operating Control Strategies And Scalability 4/2/2026

    Gain insight into a comparison of TMP and permeate control strategies for viral vector TFF, highlighting impacts on flux, processing time, impurity removal, and scale-up predictability across development.

37. Scale-Up Of AAV Production In Fixed-Bed Bioreactors 3/31/2026

    Consistent AAV production is critical for manufacturing. See how aligned strategies deliver comparable cell growth, metabolic trends, and rAAV5 titers from development through production.

38. WuXiHigh 2.0 Delivers A 180 mg/mL Formula 3/26/2026

    This case study shows how smart formulation and integrated development achieved a stable 180 mg/mL biologic for subcutaneous delivery, for teams tackling concentration issues.

39. Demonstrating Bioprocess Scalability Through Platform Consistency 3/25/2026

    Explore how a unified bioreactor design enables consistent process performance from bench to production, minimizing scale-up risk while maintaining cell growth and yield.

40. Rapid Assessment Of Fab-VHH Expression Application Of The Pfast™ Program 3/25/2026

    A systematic screen of 40 expression configurations delivered production-ready Fab-VHH conditions within 10 days, achieving 570 μg/mL titers with light chain-first orientation.